Biomarin Pharmaceutical (BMRN)
Biomarin Pharmaceutical on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
12.1M
Short interest
settlement 2026-10-15
4.9
Days to cover
-0.6 days vs prior
58.4%
Short share of volume
2026-10-28
260
Fails to deliver
settlement 2026-09-30
Mon 22 Feb
Next earnings
estimated date
-$1.2M
Insider flow, 90 days
0 buys, 1 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in BMRN is 12,050,657 shares, up 1,975,002 shares over the last month. Over the last 48 readings it ranged from 4,152,237 shares (30 May 2025) to 14,315,984 shares (15 July 2026). At the reported average volume of 2.5M shares a day that is 4.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bmrn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 12,050,657 | +4.6% | 2,458,966 | 4.90 |
| 2026-09-30 | 11,522,835 | +14.4% | 2,090,642 | 5.51 |
| 2026-09-15 | 10,075,655 | +2.0% | 1,822,750 | 5.53 |
| 2026-08-31 | 9,877,553 | -3.2% | 1,713,708 | 5.76 |
| 2026-08-14 | 10,202,950 | -18.4% | 2,767,411 | 3.69 |
| 2026-07-31 | 12,504,131 | -12.7% | 1,684,263 | 7.42 |
| 2026-07-15 | 14,315,984 | +2.9% | 1,409,304 | 10.16 |
| 2026-06-30 | 13,908,847 | +11.1% | 2,301,848 | 6.04 |
| 2026-06-15 | 12,516,448 | +7.8% | 2,066,601 | 6.06 |
| 2026-05-29 | 11,605,279 | +2.2% | 2,921,395 | 3.97 |
| 2026-05-15 | 11,359,229 | +5.3% | 2,096,087 | 5.42 |
| 2026-04-30 | 10,792,859 | +6.3% | 1,482,676 | 7.28 |
| 2026-04-15 | 10,151,216 | +14.9% | 1,581,415 | 6.42 |
| 2026-03-31 | 8,832,493 | +3.9% | 2,100,926 | 4.20 |
| 2026-03-13 | 8,501,110 | +2.9% | 1,866,101 | 4.56 |
| 2026-02-27 | 8,260,270 | -4.1% | 2,342,335 | 3.53 |
| 2026-02-13 | 8,616,736 | +8.9% | 2,203,278 | 3.91 |
| 2026-01-30 | 7,910,060 | +7.0% | 2,017,072 | 3.92 |
| 2026-01-15 | 7,393,619 | -8.2% | 2,116,537 | 3.49 |
| 2025-12-31 | 8,052,911 | -0.6% | 3,630,837 | 2.22 |
| 2025-12-15 | 8,099,003 | -1.6% | 2,147,151 | 3.77 |
| 2025-11-28 | 8,230,587 | -8.0% | 3,980,917 | 2.07 |
| 2025-11-14 | 8,949,150 | -9.3% | 2,324,608 | 3.85 |
| 2025-10-31 | 9,861,372 | +15.8% | 3,085,793 | 3.20 |
| 2025-10-15 | 8,513,411 | +19.0% | 2,260,014 | 3.77 |
| 2025-09-30 | 7,155,141 | -2.1% | 2,244,228 | 3.19 |
| 2025-09-15 | 7,307,716 | +22.7% | 1,816,459 | 4.02 |
| 2025-08-29 | 5,956,363 | +20.2% | 1,591,817 | 3.74 |
| 2025-08-15 | 4,956,158 | -3.9% | 3,210,482 | 1.54 |
| 2025-07-31 | 5,154,684 | -15.6% | 1,611,536 | 3.20 |
| 2025-07-15 | 6,109,799 | -6.3% | 2,053,522 | 2.98 |
| 2025-06-30 | 6,519,681 | +47.6% | 2,266,519 | 2.88 |
| 2025-06-13 | 4,417,385 | +6.4% | 2,079,308 | 2.12 |
| 2025-05-30 | 4,152,237 | -6.7% | 2,653,770 | 1.56 |
| 2025-05-15 | 4,449,835 | -1.2% | 1,697,863 | 2.62 |
| 2025-04-30 | 4,504,825 | -11.3% | 1,599,853 | 2.82 |
| 2025-04-15 | 5,078,137 | +8.4% | 2,358,673 | 2.15 |
| 2025-03-31 | 4,685,506 | -1.8% | 1,527,541 | 3.07 |
| 2025-03-14 | 4,769,733 | +12.5% | 1,370,046 | 3.48 |
| 2025-02-28 | 4,238,607 | -5.1% | 1,879,870 | 2.25 |
| 2025-02-14 | 4,468,117 | -0.8% | 1,064,653 | 4.20 |
| 2025-01-31 | 4,504,362 | +2.7% | 1,950,744 | 2.31 |
| 2025-01-15 | 4,384,062 | -3.5% | 1,411,181 | 3.11 |
| 2024-12-31 | 4,542,138 | -12.8% | 1,360,410 | 3.34 |
| 2024-12-13 | 5,206,764 | -9.5% | 1,584,965 | 3.29 |
| 2024-11-29 | 5,754,877 | +12.5% | 1,394,964 | 4.13 |
| 2024-11-15 | 5,116,587 | -4.9% | 1,463,914 | 3.50 |
| 2024-10-31 | 5,378,964 | -3.8% | 1,508,724 | 3.57 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of BMRN volume is 58.4%, down 8.6 points over the last five sessions. Over the last 30 readings it ranged from 29.4% (25 September 2026) to 74.2% (23 October 2026). The latest reading is 3.9 points above the 30-session average of 54.5%, on 771K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 450K | 771K | 58.4% | 0 |
| 2026-10-27 | 358K | 700K | 51.2% | 268 |
| 2026-10-26 | 632K | 1.0M | 60.5% | 6 |
| 2026-10-23 | 458K | 617K | 74.2% | 179 |
| 2026-10-22 | 493K | 839K | 58.7% | 70 |
| 2026-10-21 | 620K | 925K | 67.0% | 17 |
| 2026-10-20 | 725K | 1.2M | 59.1% | 128 |
| 2026-10-19 | 720K | 1.2M | 60.7% | 2,165 |
| 2026-10-16 | 649K | 1.0M | 62.0% | 62 |
| 2026-10-15 | 685K | 995K | 68.8% | 4 |
| 2026-10-14 | 245K | 608K | 40.4% | 0 |
| 2026-10-13 | 429K | 948K | 45.3% | 287 |
| 2026-10-12 | 440K | 1.0M | 43.6% | 110 |
| 2026-10-09 | 447K | 683K | 65.5% | 0 |
| 2026-10-08 | 464K | 681K | 68.0% | 0 |
| 2026-10-07 | 469K | 830K | 56.5% | 0 |
| 2026-10-06 | 502K | 1.2M | 40.5% | 1,748 |
| 2026-10-05 | 496K | 805K | 61.6% | 3 |
| 2026-10-02 | 339K | 596K | 56.9% | 18 |
| 2026-10-01 | 389K | 773K | 50.4% | 400 |
| 2026-09-30 | 333K | 549K | 60.6% | 31 |
| 2026-09-29 | 389K | 691K | 56.2% | 75 |
| 2026-09-28 | 420K | 908K | 46.2% | 0 |
| 2026-09-25 | 165K | 560K | 29.4% | 111 |
| 2026-09-24 | 210K | 480K | 43.7% | 500 |
| 2026-09-23 | 432K | 935K | 46.2% | 100 |
| 2026-09-22 | 385K | 935K | 41.2% | 7 |
| 2026-09-21 | 239K | 654K | 36.5% | 513 |
| 2026-09-18 | 313K | 541K | 57.8% | 7,985 |
| 2026-09-17 | 334K | 482K | 69.4% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in BMRN is 260 shares, down 563 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (22 April 2026) to 65,600 shares (31 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 260 | $59.87 | $16K |
| 2026-09-21 | 823 | $63.94 | $53K |
| 2026-09-18 | 23,037 | $65.08 | $1.5M |
| 2026-09-17 | 861 | $64.73 | $56K |
| 2026-09-02 | 47,834 | $64.84 | $3.1M |
| 2026-08-24 | 260 | $66.70 | $17K |
| 2026-08-11 | 5,650 | $68.88 | $389K |
| 2026-08-07 | 29,279 | $61.46 | $1.8M |
| 2026-08-04 | 97 | $60.00 | $6K |
| 2026-07-30 | 74 | $61.37 | $5K |
| 2026-07-29 | 3,200 | $62.07 | $199K |
| 2026-07-27 | 236 | $59.33 | $14K |
| 2026-07-24 | 236 | $58.87 | $14K |
| 2026-07-23 | 4 | $58.40 | $234 |
| 2026-07-10 | 114 | $59.97 | $7K |
| 2026-07-09 | 83 | $59.75 | $5K |
| 2026-07-01 | 15 | $57.22 | $858 |
| 2026-06-30 | 23 | $57.67 | $1K |
| 2026-06-29 | 1,700 | $59.00 | $100K |
| 2026-06-15 | 689 | $55.95 | $39K |
| 2026-06-12 | 114 | $55.54 | $6K |
| 2026-06-10 | 122 | $57.91 | $7K |
| 2026-06-05 | 1,565 | $56.47 | $88K |
| 2026-06-01 | 2,853 | $57.29 | $163K |
| 2026-05-26 | 1,367 | $54.09 | $74K |
| 2026-05-22 | 12,281 | $54.10 | $664K |
| 2026-04-28 | 753 | $53.81 | $41K |
| 2026-04-27 | 30 | $53.18 | $2K |
| 2026-04-22 | 1 | $54.62 | $55 |
| 2026-03-31 | 65,600 | $54.79 | $3.6M |
Insider trades
SEC Form 4, newest first. JSONInsiders at BMRN reported 1 open-market sell worth $1.2M in the last 90 days and no open-market buys. Latest filing: Friberg Gregory R (EVP, Chief R&D Officer) on 2026-09-30.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Friberg Gregory R | EVP, Chief R&D Officer | Tax withholding | 4K | $60.00 | $245K | 48K |
| 2026-09-10 | Plenge Robert M | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2026-09-02 | Davis George Eric | EVP, Chief Legal Officer | Sell | 18K | $66.28 | $1.2M | 61K |
| 2026-06-02 | Countouriotis Athena | Director | Grant | 7K | $0.00 | $0 | 21K |
| 2026-06-02 | Walbert Timothy P | Director | Grant | 7K | $0.00 | $0 | 17K |
| 2026-06-02 | Ho Maykin | Director | Grant | 7K | $0.00 | $0 | 36K |
| 2026-06-02 | HOMBACH ROBERT J. | Director | Grant | 7K | $0.00 | $0 | 49K |
| 2026-06-02 | Enyedy Mark J | Director | Grant | 7K | $0.00 | $0 | 21K |
| 2026-06-02 | Dere Willard H | Director | Grant | 7K | $0.00 | $0 | 46K |
| 2026-06-02 | CLARK IAN T | Director | Grant | 7K | $0.00 | $0 | 14K |
| 2026-06-02 | Bodem Barbara W. | Director | Grant | 7K | $0.00 | $0 | 21K |
| 2026-06-02 | ANDERSON ELIZABETH M | Director | Grant | 7K | $0.00 | $0 | 42K |
| 2026-05-20 | Hubbard Cristin | EVP, Chief Commercial Officer | Tax withholding | 2K | $50.20 | $116K | 42K |
| 2026-05-07 | Friberg Gregory R | EVP, Chief R&D Officer | Sell | 3K | $53.85 | $177K | 52K |
| 2026-03-18 | Davis George Eric | EVP, Chief Legal Officer | Tax withholding | 1K | $56.05 | $71K | 79K |
| 2026-03-17 | Hubbard Cristin | EVP, Chief Commercial Officer | Tax withholding | 1K | $56.05 | $70K | 45K |
| 2026-03-17 | Friberg Gregory R | EVP, Chief R&D Officer | Tax withholding | 2K | $56.05 | $91K | 55K |
| 2026-03-17 | Guyer Charles Greg | EVP, Chief Technical Officer | Tax withholding | 2K | $56.05 | $95K | 84K |
| 2026-03-17 | Mueller Brian | EVP, Chief Financial Officer | Tax withholding | 2K | $56.05 | $119K | 123K |
| 2026-03-17 | Hardy Alexander | Chief Executive Officer | Tax withholding | 4K | $56.05 | $238K | 215K |
| 2026-03-16 | Guyer Charles Greg | EVP, Chief Technical Officer | Grant | 15K | $0.00 | $0 | 86K |
| 2026-03-16 | Davis George Eric | EVP, Chief Legal Officer | Grant | 15K | $0.00 | $0 | 80K |
| 2026-03-16 | Davis George Eric | EVP, Chief Legal Officer | Tax withholding | 7K | $58.51 | $420K | 65K |
| 2026-03-16 | Mueller Brian | EVP, Chief Financial Officer | Grant | 19K | $0.00 | $0 | 125K |
| 2026-03-16 | Hardy Alexander | Chief Executive Officer | Grant | 62K | $0.00 | $0 | 219K |
| 2026-03-16 | Hubbard Cristin | EVP, Chief Commercial Officer | Grant | 15K | $0.00 | $0 | 46K |
| 2026-03-16 | Friberg Gregory R | EVP, Chief R&D Officer | Grant | 19K | $0.00 | $0 | 57K |
| 2026-03-13 | Guyer Charles Greg | EVP, Chief Technical Officer | Tax withholding | 9K | $58.51 | $533K | 71K |
| 2026-03-13 | Mueller Brian | EVP, Chief Financial Officer | Tax withholding | 10K | $58.51 | $582K | 107K |
| 2026-03-13 | Hardy Alexander | Chief Executive Officer | Tax withholding | 3K | $58.51 | $172K | 156K |
| 2026-03-11 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 16K | $60.46 | $997K | 80K |
| 2026-02-26 | Friberg Gregory R | EVP, Chief R&D Officer | Sell | 6K | $60.38 | $382K | 38K |
| 2026-02-26 | Davis George Eric | EVP, Chief Legal Officer | Sell | 26K | $61.36 | $1.6M | 72K |
| 2026-02-25 | Guyer Charles Greg | EVP, Chief Technical Officer | Grant | 2K | $0.00 | $0 | 96K |
| 2026-02-25 | Guyer Charles Greg | EVP, Chief Technical Officer | Grant | 7K | $0.00 | $0 | 94K |
| 2026-02-25 | Guyer Charles Greg | EVP, Chief Technical Officer | Grant | 6K | $0.00 | $0 | 87K |
| 2026-02-25 | Davis George Eric | EVP, Chief Legal Officer | Grant | 2K | $0.00 | $0 | 99K |
| 2026-02-25 | Davis George Eric | EVP, Chief Legal Officer | Grant | 7K | $0.00 | $0 | 96K |
| 2026-02-25 | Davis George Eric | EVP, Chief Legal Officer | Grant | 6K | $0.00 | $0 | 89K |
| 2026-02-25 | Mueller Brian | EVP, Chief Financial Officer | Grant | 3K | $0.00 | $0 | 117K |
| 2026-02-25 | Mueller Brian | EVP, Chief Financial Officer | Grant | 7K | $0.00 | $0 | 114K |
| 2026-02-25 | Mueller Brian | EVP, Chief Financial Officer | Grant | 7K | $0.00 | $0 | 107K |
| 2026-01-20 | Ramchandani Rashmi Virendra | VP, Chief Accounting Officer | Grant | 7K | $0.00 | $0 | 26K |
| 2026-01-20 | Ramchandani Rashmi Virendra | VP, Chief Accounting Officer | Grant | 19K | $0.00 | $0 | 19K |
| 2025-12-01 | Hardy Alexander | Chief Executive Officer | Tax withholding | 17K | $55.03 | $912K | 159K |
| 2025-09-30 | Friberg Gregory R | EVP, Chief R&D Officer | Tax withholding | 3K | $54.16 | $179K | 44K |
| 2025-08-01 | CLARK IAN T | Director | Grant | 7K | $0.00 | $0 | 7K |
| 2025-05-20 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 2K | $59.31 | $106K | 14K |
| 2025-05-20 | ANDERSON ELIZABETH M | Director | Grant | 7K | $0.00 | $0 | 34K |
| 2025-05-20 | Bodem Barbara W. | Director | Grant | 7K | $0.00 | $0 | 14K |
| 2025-05-20 | Countouriotis Athena | Director | Grant | 7K | $0.00 | $0 | 14K |
| 2025-05-20 | Dere Willard H | Director | Grant | 7K | $0.00 | $0 | 39K |
| 2025-05-20 | Enyedy Mark J | Director | Grant | 7K | $0.00 | $0 | 14K |
| 2025-05-20 | Ho Maykin | Director | Grant | 7K | $0.00 | $0 | 28K |
| 2025-05-20 | HOMBACH ROBERT J. | Director | Grant | 7K | $0.00 | $0 | 42K |
| 2025-05-20 | MEIER RICHARD A | Director | Grant | 7K | $0.00 | $0 | 127K |
| 2025-05-20 | Walbert Timothy P | Director | Grant | 7K | $0.00 | $0 | 10K |
| 2025-05-20 | Hubbard Cristin | EVP, Chief Commercial Officer | Tax withholding | 2K | $59.93 | $129K | 31K |
| 2025-05-19 | Burkhart Erin | GVP, Chief Accounting Officer | Tax withholding | 996 | $59.27 | $59K | 16K |
| 2025-05-02 | Hubbard Cristin | EVP, Chief Commercial Officer | Sell | 273 | $64.92 | $18K | 33K |
| 2025-04-30 | Hubbard Cristin | EVP, Chief Commercial Officer | Grant | 273 | $54.14 | $15K | 33K |
| 2025-04-30 | Hardy Alexander | Chief Executive Officer | Grant | 375 | $54.14 | $20K | 176K |
| 2025-03-19 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 1K | $71.52 | $93K | 17K |
| 2025-03-17 | Hardy Alexander | Chief Executive Officer | Grant | 44K | $0.00 | $0 | 176K |
| 2025-03-17 | Mueller Brian | EVP, Chief Financial Officer | Grant | 17K | $0.00 | $0 | 100K |
| 2025-03-17 | Guyer Charles Greg | EVP, Chief Technical Officer | Grant | 13K | $0.00 | $0 | 81K |
| 2025-03-17 | Friberg Gregory R | EVP, Chief R&D Officer | Grant | 18K | $0.00 | $0 | 47K |
| 2025-03-17 | Hubbard Cristin | EVP, Chief Commercial Officer | Grant | 13K | $0.00 | $0 | 33K |
| 2025-03-17 | Davis George Eric | EVP, Chief Legal Officer | Grant | 13K | $0.00 | $0 | 83K |
| 2025-03-17 | Burkhart Erin | GVP, Chief Accounting Officer | Grant | 6K | $0.00 | $0 | 18K |
| 2025-03-14 | Hardy Alexander | Chief Executive Officer | Tax withholding | 3K | $69.44 | $204K | 131K |
| 2025-03-14 | Mueller Brian | EVP, Chief Financial Officer | Tax withholding | 18K | $69.44 | $1.3M | 83K |
| 2025-03-14 | Guyer Charles Greg | EVP, Chief Technical Officer | Tax withholding | 20K | $69.44 | $1.4M | 68K |
| 2025-03-14 | Davis George Eric | EVP, Chief Legal Officer | Tax withholding | 16K | $69.44 | $1.1M | 70K |
| 2025-03-14 | Burkhart Erin | GVP, Chief Accounting Officer | Tax withholding | 823 | $69.44 | $57K | 12K |
| 2025-03-06 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 7K | $71.28 | $501K | 88K |
| 2025-02-28 | Guyer Charles Greg | EVP, Chief Technical Officer | Tax withholding | 4K | $71.16 | $305K | 95K |
| 2025-02-25 | Davis George Eric | EVP, Chief Legal Officer | Grant | 9K | $0.00 | $0 | 86K |
| 2025-02-25 | Davis George Eric | EVP, Chief Legal Officer | Grant | 11K | $0.00 | $0 | 67K |
| 2025-02-25 | Davis George Eric | EVP, Chief Legal Officer | Grant | 10K | $0.00 | $0 | 77K |
| 2025-02-25 | Guyer Charles Greg | EVP, Chief Technical Officer | Grant | 10K | $0.00 | $0 | 90K |
| 2025-02-25 | Guyer Charles Greg | EVP, Chief Technical Officer | Grant | 9K | $0.00 | $0 | 99K |
| 2025-02-25 | Guyer Charles Greg | EVP, Chief Technical Officer | Grant | 11K | $0.00 | $0 | 80K |
| 2025-02-25 | Mueller Brian | EVP, Chief Financial Officer | Grant | 10K | $0.00 | $0 | 92K |
| 2025-02-25 | Mueller Brian | EVP, Chief Financial Officer | Grant | 9K | $0.00 | $0 | 102K |
| 2025-02-25 | Mueller Brian | EVP, Chief Financial Officer | Grant | 11K | $0.00 | $0 | 83K |
| 2025-02-24 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 1K | $68.38 | $92K | 13K |
| 2025-02-24 | Walbert Timothy P | Director | Grant | 3K | $0.00 | $0 | 3K |
| 2024-11-29 | Hardy Alexander | Chief Executive Officer | Tax withholding | 14K | $66.03 | $944K | 134K |
| 2024-11-12 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 5K | $66.37 | $350K | 69K |
| 2024-10-31 | Guyer Charles Greg | EVP, Chief Technical Officer | Grant | 55 | $56.01 | $3K | 74K |
| 2024-10-31 | Hardy Alexander | Chief Executive Officer | Grant | 300 | $56.01 | $17K | 148K |
| 2024-09-30 | Friberg Gregory R | EVP, Chief R&D Officer | Grant | 8K | $0.00 | $0 | 29K |
| 2024-09-30 | Friberg Gregory R | EVP, Chief R&D Officer | Grant | 21K | $0.00 | $0 | 21K |
| 2024-09-13 | FUCHS HENRY J | President, Worldwide R&D | Tax withholding | 12K | $84.90 | $1.0M | 185K |
| 2024-08-13 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 714 | $90.00 | $64K | 14K |
| 2024-06-28 | Mueller Brian | EVP, Chief Financial Officer | Tax withholding | 588 | $82.33 | $48K | 72K |
| 2024-06-03 | MEIER RICHARD A | Director | Exercise or conversion | 7K | $63.10 | $416K | 126K |
| 2024-06-03 | MEIER RICHARD A | Director | Tax withholding | 5K | $76.41 | $417K | 121K |
| 2024-06-03 | HERON ELAINE J | Director | Exercise or conversion | 5K | $63.10 | $318K | 102K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON5 Form 144 notices on file for BMRN worth $4.3M at the prices reported; 1 in the last 90 days worth $1.2M. Latest: Davis George Eric filed on 2026-09-02 to sell 17,557 shares ($1.2M) from 2026-09-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-02 | Davis George EricOfficer | 18K | $1.2M | 0.009% | 2026-09-02 | Fidelity Brokerage Services LLC |
| 2026-05-07 | Friberg Gregory ROfficer | 3K | $177K | 0.002% | 2026-05-07 | Fidelity Brokerage Services LLC |
| 2026-03-11 | Guyer Charles GregOfficer | 16K | $997K | 0.009% | 2026-03-11 | Fidelity Brokerage Services LLC |
| 2026-02-26 | Friberg Gregory ROfficer | 6K | $382K | 0.003% | 2026-02-26 | Fidelity Brokerage Services LLC |
| 2026-02-26 | Davis George EricOfficer | 26K | $1.6M | 0.014% | 2026-02-26 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of BMRN in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 9.1% of the class (17,560,751 shares), filed 2026-01-21 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 10.1M | 5.3% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 12 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-01-21 | 13G/Ano. 13 | BlackRock, Inc.parent holding company | 17.6M | 9.1% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 2 | Shabet Rose Sharonindividual | 8.3M | 4.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | VIKING GLOBAL INVESTORS LPpartnership | 8.3M | 4.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | HALVORSEN OLE ANDREASindividual | 8.3M | 4.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Ott David C.individual | 8.3M | 4.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Viking Global Equities Master Ltd.corporation | 5.3M | 2.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | VIKING GLOBAL PERFORMANCE LLCother entity | 5.4M | 2.8% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Viking Long Fund GP LLCother entity | 2.1M | 1.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Viking Long Fund Master Ltd.corporation | 2.1M | 1.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Viking Global Opportunities Portfolio GP LLCother entity | 831K | 0.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Viking Global Opportunities Liquid Portfolio Sub-Master LPpartnership | 831K | 0.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Viking Global Opportunities GP LLCother entity | 831K | 0.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Viking Global Opportunities Parent GP LLCother entity | 831K | 0.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Viking Global Equities II LPpartnership | 108K | 0.1% | 2025-09-30 |
13F holders
Tracked managers holding BMRN at their latest 13F. JSON9 of the 30 tracked managers held BMRN at their latest 13F, $991.7M in total at quarter-end prices. Viking Global Investors is the largest at $435.8M (1.2% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 7 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Viking Global Investors | 2026-06-30 | 7.6M | $435.8M | 1.24% | +554K |
| AQR Capital Management | 2026-06-30 | 5.7M | $322.5M | 0.11% | -2.0M |
| Millennium Management | 2026-06-30 | 2.1M | $118.5M | 0.04% | -938K |
| Citadel Advisors | 2026-06-30 | 1.1M | $64.2M | 0.01% | -3.4M |
| Renaissance Technologies | 2026-06-30 | 452K | $25.9M | 0.04% | -573K |
| Bridgewater Associates | 2026-06-30 | 275K | $15.7M | 0.06% | +68K |
| D. E. Shaw & Co. | 2026-06-30 | 92K | $5.3M | 0.00% | -190K |
| Fisher Asset Management | 2026-06-30 | 35K | $2.0M | 0.00% | -91 |
| Two Sigma Investments | 2026-06-30 | 29K | $1.6M | 0.00% | -16K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Biomarin Pharmaceutical reported revenue of $989.7M, up 19.9% from the same quarter a year earlier, and net income of $44.8M (0.23 diluted EPS). In FY 2025 it generated $828.0M of operating cash flow. As of 2026-06-30, cash was $874.0M against $4.19B of debt.
- Cash
- $874.0M
- Debt
- $4.19B
- Equity
- $6.32B
- Total assets
- $11.72B
- Shares outstanding
- 193,573,759
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $989.7M | $44.8M | 4.5% | 0.23 |
| Q1 FY 2026 | 2026-03-31 | $766.2M | $105.5M | 13.8% | 0.54 |
| Q4 FY 2025derived | 2025-12-31 | $874.6M | -$46.6M | -5.3% | n/a |
| Q3 FY 2025 | 2025-09-30 | $776.1M | -$30.7M | -4.0% | -0.16 |
| Q2 FY 2025 | 2025-06-30 | $825.4M | $240.5M | 29.1% | 1.23 |
| Q1 FY 2025 | 2025-03-31 | $745.1M | $185.7M | 24.9% | 0.95 |
| Q4 FY 2024derived | 2024-12-31 | $747.3M | $124.9M | 16.7% | n/a |
| Q3 FY 2024 | 2024-09-30 | $745.7M | $106.1M | 14.2% | 0.55 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $3.22B | $348.9M | $828.0M | $103.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $2.85B | $426.9M | $572.8M | $85.4M | n/a | n/a |
| FY 2023 | 2023-12-31 | $2.42B | $167.6M | $159.3M | $96.7M | n/a | n/a |
| FY 2022 | 2022-12-31 | $2.10B | $141.6M | $175.9M | $121.0M | $0 | n/a |
| FY 2021 | 2021-12-31 | $1.85B | -$64.1M | $304.5M | $95.6M | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-28 from the cover page.
What this page is
Biomarin Pharmaceutical in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Biomarin Pharmaceutical (BMRN), SEC CIK 1048477, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-04-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-30.JSON and CSV
- Company record
- EDGAR filing index for CIK 1048477Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of BMRN is sold short?
12,050,657 shares were held short at the 2026-10-15 settlement, 4.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is BMRN's daily short volume?
On 2026-10-28, 450,033 of the 770,528 BMRN shares reported to FINRA were sold short, 58.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does BMRN have fails to deliver?
The SEC's latest file shows 260 BMRN shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are BMRN insiders buying or selling?
Insiders at BMRN reported 1 open-market sell worth $1.2M in the last 90 days and no open-market buys. Latest filing: Friberg Gregory R (EVP, Chief R&D Officer) on 2026-09-30.
Have BMRN insiders filed to sell?
5 Form 144 notices on file for BMRN worth $4.3M at the prices reported; 1 in the last 90 days worth $1.2M. Latest: Davis George Eric filed on 2026-09-02 to sell 17,557 shares ($1.2M) from 2026-09-02.
Who owns 5% or more of BMRN?
2 holders report 5% or more of BMRN in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 9.1% of the class (17,560,751 shares), filed 2026-01-21 for an event on 2025-12-31.
What did BMRN report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Biomarin Pharmaceutical reported revenue of $989.7M, up 19.9% from the same quarter a year earlier, and net income of $44.8M (0.23 diluted EPS). In FY 2025 it generated $828.0M of operating cash flow. As of 2026-06-30, cash was $874.0M against $4.19B of debt.
Which tracked 13F managers own BMRN?
9 of the 30 tracked 13F managers held BMRN shares at their latest filing, $991.7M in all. The largest: Andreas Halvorsen's Viking Global Investors (7.6M shares, $435.8M), Cliff Asness's AQR Capital Management (5.7M shares, $322.5M), Izzy Englander's Millennium Management (2.1M shares, $118.5M), Ken Griffin's Citadel Advisors (1.1M shares, $64.2M), Renaissance Technologies (452K shares, $25.9M), Ray Dalio's Bridgewater Associates (275K shares, $15.7M). The table above lists all 9.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.